This suggests that the use of PD-1/PD-L1 as the sole predictive biomarker for tumor immunotherapy remains problematic and how to identify patients who may benefit from the anti-PD-1/anti-PD-L1therapy is a critical clinic bottleneck. Here, PDCD1 is linked to neoplasm.